Moderna sees strong reason to believe 2021 won’t be a one-off year for the biotech given the anticipated need for booster shots and additional supply deals coupled with stronger pricing power, according to a note from Jefferies analysts. In turn, analysts estimate that Moderna could generate $15 billion in 2022, with an upper limit of $30 billion.